journal article·2024-02Open access

Erythrocyte‐Leveraged Oncolytic Virotherapy (ELeOVt): Oncolytic Virus Assembly on Erythrocyte Surface to Combat Pulmonary Metastasis and Alleviate Side Effects

Mingyang Liu, Ruizhe Zhang, Hanwei Huang, Pengfei Liu, Xu Zhao, Hu Wu, Ying He, Ruizhe Xu, Xifeng Qin, Zhenguo Cheng, Hongyu Liu, Onder Ergonul, Füsun Can, Defang Ouyang, Zhenning Wang, Zhiqing Pang, Funan Liu

Advanced Science· Volume 11· Issue 5

Abstract

Abstract Despite being a new promising tool for cancer therapy, intravenous delivery of oncolytic viruses (OVs) is greatly limited by poor tumor targeting, rapid clearance in the blood, severe organ toxicity, and cytokine release syndrome. Herein, a simple and efficient strategy of erythrocyte‐leveraged oncolytic virotherapy (ELeOVt) is reported, which for the first time assembled OVs on the surface of erythrocytes with up to near 100% efficiency and allowed targeted delivery of OVs to the lung after intravenous injection to achieve excellent treatment of pulmonary metastases while greatly improving the biocompatibility of OVs as a drug. Polyethyleneimine (PEI) as a bridge to assemble OVs on erythrocytes also played an important role in promoting the transfection of OVs. It is found that ELeOVt approach significantly prolonged the circulation time of OVs and increased the OVs distribution in the lung by more than tenfold, thereby significantly improving the treatment of lung metastases while reducing organ and systemic toxicity. Taken together, these findings suggest that the ELeOVt provides a biocompatible, efficient, and widely available approach to empower OVs to combat lung metastasis.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Virus-based gene therapy research · RNA Interference and Gene Delivery · Bacteriophages and microbial interactions

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Surgical Oncology and General Surgery The First Hospital of China Medical University 155 North Nanjing Street, Heping District Shenyang 110001 China

Department of Pharmaceutics School of Pharmacy Fudan University and Key Laboratory of Smart Drug Delivery Ministry of Education Shanghai 201203 China

Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors China Medical University Ministry of Education 155 North Nanjing Street, Heping District Shenyang 110001 China

Sino‐British Research Centre for Molecular Oncology National Centre for International Research in Cell and Gene Therapy School of Basic Medical Sciences Academy of Medical Sciences Zhengzhou University Zhengzhou 450052 China

Koç University Iş Bank Center for Infectious Diseases (KUISCID) Koç University School of Medicine and American Hospital Istanbul 34010 Turkey

State Key Laboratory of Quality Research in Chinese Medicine Institute of Chinese Medical Sciences (ICMS) University of Macau Macau 999078 China

Phase I Clinical Trials Center The First Hospital China Medical University 518 North Chuangxin Road, Baita Street, Hunnan District Shenyang Liaoning 110102 China

Funding

National Key Research and Development Program of China · National Natural Science Foundation of China · Liaoning Revitalization Talents Program

References (65)

Show source-provided references
1. 10.3322/caac.2176310.3322/caac.21763 ↗
2. 10.1038/s41591-020-01195-410.1038/s41591-020-01195-4 ↗
3. 10.1200/JCO.19.0314110.1200/JCO.19.03141 ↗
4. 10.1016/j.ccell.2022.04.00210.1016/j.ccell.2022.04.002 ↗
5. 10.3322/caac.2173110.3322/caac.21731 ↗
6. 10.3322/caac.2149210.3322/caac.21492 ↗
7. 10.1038/s41571-021-00501-410.1038/s41571-021-00501-4 ↗
8. 10.3389/fimmu.2021.72183010.3389/fimmu.2021.721830 ↗
9. 10.1136/jitc-2021-00416710.1136/jitc-2021-004167 ↗
10. 10.1016/j.cclet.2021.05.00110.1016/j.cclet.2021.05.001 ↗
11. 10.1038/s41467-021-26003-610.1038/s41467-021-26003-6 ↗
12. 10.1016/j.nantod.2022.10167110.1016/j.nantod.2022.101671 ↗
13. 10.1002/adma.20221221010.1002/adma.202212210 ↗
14. 10.1038/s41467-019-13744-810.1038/s41467-019-13744-8 ↗
15. 10.1038/s41467-017-01385-810.1038/s41467-017-01385-8 ↗
16. 10.3390/cancers1010035610.3390/cancers10100356 ↗
17. 10.21037/cco.2018.04.0410.21037/cco.2018.04.04 ↗
18. 10.1007/s12274-021-4031-610.1007/s12274-021-4031-6 ↗
19. 10.1016/j.cclet.2021.10.07410.1016/j.cclet.2021.10.074 ↗
20. 10.1038/nrd.2016.17810.1038/nrd.2016.178 ↗
21. 10.1016/j.cell.2017.08.02710.1016/j.cell.2017.08.027 ↗
22. 10.1038/s41573-019-0029-010.1038/s41573-019-0029-0 ↗
23. 10.1038/s41571-022-00719-w10.1038/s41571-022-00719-w ↗
24. 10.1186/s40425-018-0458-z10.1186/s40425-018-0458-z ↗
25. 10.1136/jitc-2020-00148610.1136/jitc-2020-001486 ↗
26. 10.1001/jamaoncol.2016.206410.1001/jamaoncol.2016.2064 ↗
27. 10.1126/scitranslmed.aam757710.1126/scitranslmed.aam7577 ↗
28. 10.1111/cas.1302710.1111/cas.13027 ↗
29. 10.1038/s41392-023-01365-z10.1038/s41392-023-01365-z ↗
30. 10.1016/j.pharmthera.2020.10758610.1016/j.pharmthera.2020.107586 ↗
31. 10.1016/j.ymthe.2006.01.00310.1016/j.ymthe.2006.01.003 ↗
32. 10.1182/blood-2008-09-17845910.1182/blood-2008-09-178459 ↗
33. 10.3201/eid1803.11123810.3201/eid1803.111238 ↗
34. 10.1093/ofid/ofz01710.1093/ofid/ofz017 ↗
35. 10.1016/j.ajt.2022.10.00210.1016/j.ajt.2022.10.002 ↗
36. 10.1007/s15010-022-01945-110.1007/s15010-022-01945-1 ↗
37. 10.1038/sj.mt.630031910.1038/sj.mt.6300319 ↗
38. 10.3390/biomedicines1007169710.3390/biomedicines10071697 ↗
39. 10.1016/j.omto.2022.02.00410.1016/j.omto.2022.02.004 ↗
40. 10.1089/1043034995001836410.1089/10430349950018364 ↗
41. 10.1517/17425247.2016.115870710.1517/17425247.2016.1158707 ↗
42. 10.1515/BC.2007.06110.1515/BC.2007.061 ↗
43. 10.3322/canjclin.33.2.7410.3322/canjclin.33.2.74 ↗
44. 10.1016/j.jconrel.2022.04.00810.1016/j.jconrel.2022.04.008 ↗
45. 10.1002/wnan.167010.1002/wnan.1670 ↗
46. 10.1002/advs.20190324310.1002/advs.201903243 ↗
47. 10.1016/j.bioactmat.2023.02.01510.1016/j.bioactmat.2023.02.015 ↗
48. 10.1016/j.biomaterials.2022.12176310.1016/j.biomaterials.2022.121763 ↗
49. 10.1039/D0BM00681E10.1039/D0BM00681E ↗
50. 10.1016/j.apsb.2023.03.00110.1016/j.apsb.2023.03.001 ↗
51. 10.1002/EXP.2021008110.1002/EXP.20210081 ↗
52. 10.3390/pharmaceutics1502041010.3390/pharmaceutics15020410 ↗
53. 10.1080/17425247.2022.213176710.1080/17425247.2022.2131767 ↗
54. 10.1016/j.cej.2022.14093010.1016/j.cej.2022.140930 ↗
55. 10.1021/acs.nanolett.8b0068910.1021/acs.nanolett.8b00689 ↗
56. 10.1016/j.apsb.2022.03.01110.1016/j.apsb.2022.03.011 ↗
57. 10.1002/EXP.2021021710.1002/EXP.20210217 ↗
58. 10.1038/s41586-022-05028-x10.1038/s41586-022-05028-x ↗
59. 10.1126/sciadv.aax925010.1126/sciadv.aax9250 ↗
60. 10.1038/s41551-020-00644-210.1038/s41551-020-00644-2 ↗
61. 10.1038/s41467-018-05079-710.1038/s41467-018-05079-7 ↗
62. 10.1002/adma.20221221010.1002/adma.202212210 ↗
63. 10.1158/0008-5472.CAN-12-305610.1158/0008-5472.CAN-12-3056 ↗
64. 10.1158/1078-0432.CCR-16-047710.1158/1078-0432.CCR-16-0477 ↗
65. 10.1016/j.ymthe.2022.11.01610.1016/j.ymthe.2022.11.016 ↗